Table 1.
Baseline features of the study population according to the outcome of SBT
| Characteristics |
Successful SBT |
Failed SBT |
P value |
|---|---|---|---|
| ( n = 77) | ( n = 24) | ||
| Age, years |
65 ± 18 |
71 ± 16 |
0.186 |
| ≧65 years |
45 (58) |
17 (71) |
0.276 |
| Male sex |
54 (70) |
12 (50) |
0.070 |
| Body mass index |
22 ± 4 |
23 ± 4 |
0.378 |
| APACHE II |
17 ± 6 |
16 ± 7 |
0.767 |
| Comorbidities |
|
|
|
| Cerebrovascular disease |
16 (21) |
4 (17) |
0.776 |
| COPD |
19 (25) |
7 (29) |
0.660 |
| Heart failure |
3 (4) |
1 (4) |
0.999 |
| Liver cirrhosis |
4 (5) |
1 (4) |
0.999 |
| End-stage renal disease |
6 (8) |
2 (8) |
0.999 |
| Diabetes mellitus |
26 (34) |
6 (25) |
0.420 |
| Hypertension |
30 (39) |
8 (33) |
0.619 |
| Coronary artery disease |
5 (7) |
3 (13) |
0.391 |
| Cause of acute respiratory failure |
|
|
|
| Pneumonia |
34 (44) |
15 (63) |
0.116 |
| Sepsis |
15 (20) |
3 (13) |
0.551 |
| Acute exacerbation of COPD |
3 (4) |
1 (4) |
0.999 |
| Gastrointestinal bleeding |
10 (13) |
1 (4) |
0.452 |
| Lung edema |
4 (5) |
1 (4) |
0.999 |
| Neurologic disease |
6 (8) |
3 (13) |
0.440 |
| Others |
5 (7) |
0 (0) |
0.335 |
| Time to first SBT, hours |
96 ± 103 |
94 ± 71 |
0.931 |
| Medications |
|
|
|
| β2 agonist |
28 (36) |
17 (71) |
0.003 |
| Anticholinergic |
22 (29) |
16 (67) |
0.001 |
| ACEI/ARB |
8 (10) |
2 (8) |
0.999 |
| CCB |
27 (35) |
13 (54) |
0.095 |
| β blocker | 11 (14) | 3 (13) | 0.999 |
Data are presented as mean ± standard deviation or number (%).
ACEI, angiotensin-converting-enzyme inhibitor; APACHE, acute physiology and chronic health evaluation; ARB, angiotensin-receptor blocker; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; SBT, spontaneous breathing trial.